Expertise in
24
conditions

Takanori Teshima

Sapporo, JP 
Expertise in
24
conditions
Sapporo, JP 
OverviewLocationsClinical Research

Overview

Takanori Teshima practices in Sapporo, Japan. Mr. Teshima is highly rated in 24 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Hepatic Venoocclusive Disease with Immunodeficiency, Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 405 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Sapporo, Japan
Other Locations
Japan
Hachioji, Japan
Tokyo, 1808602, Japan
Fukuoka, Japan
Hakodate, 0418680, Japan
Musashino, 1808602, Japan
Higashi, 8128582, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Completed
Publish Date: May 01, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
An Open-Label Single-Arm Phase 1 Study Evaluating Safety of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects
An Open-Label Single-Arm Phase 1 Study Evaluating Safety of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects
Enrollment Status: Completed
Publish Date: March 03, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

405 Total Publications

Is Age No Longer a Barrier to Allogeneic Hematopoietic Stem Cell Transplantation?
Is Age No Longer a Barrier to Allogeneic Hematopoietic Stem Cell Transplantation?
Journal: Transplantation
Published: June 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Teshima's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 14 Advanced Conditions
View All 78 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile